<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2312-3893</journal-id>
<journal-title><![CDATA[Revista Virtual de la Sociedad Paraguaya de Medicina Interna]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. virtual Soc. Parag. Med. Int.]]></abbrev-journal-title>
<issn>2312-3893</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Paraguaya de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2312-38932018000200019</article-id>
<article-id pub-id-type="doi">10.18004/rvspmi/2312-3893/2018.05(02)19-029</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Preferencias de Reumatólogos del Ecuador sobre el tratamiento de la artritis reumatoide]]></article-title>
<article-title xml:lang="en"><![CDATA[Preferences of Rheumatologists of Ecuador on the treatment of rheumatoid arthritis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ríos Acosta]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vallejo]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calapaqui Aguirre]]></surname>
<given-names><![CDATA[Wendy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[Angélica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres Toala]]></surname>
<given-names><![CDATA[Fausto Gady]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Reumatología y Rehabilitación  ]]></institution>
<addr-line><![CDATA[Quito ]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Pontificia Universidad Católica del Ecuador  ]]></institution>
<addr-line><![CDATA[Quito ]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Ecuatoriano de Seguridad Social Centro de atención ambulatoria &#8220;El Batán&#8221; ]]></institution>
<addr-line><![CDATA[Quito ]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Eugenio Espejo.  ]]></institution>
<addr-line><![CDATA[Quito ]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Pontificia Universidad Católica del Ecuador Makroscopio Servicios de Salud ]]></institution>
<addr-line><![CDATA[Quito ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2018</year>
</pub-date>
<volume>5</volume>
<numero>2</numero>
<fpage>19</fpage>
<lpage>29</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2312-38932018000200019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2312-38932018000200019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2312-38932018000200019&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: los medicamentos para el manejo de la artritis reumatoide (AR), especialmente los biológicos y los aprobados recientemente, están en un proceso de disminuir la invasividad de su vía de administración. La investigación terapéutica avanza cada día en el desarrollo de nuevas fórmulas que se basan en mayor efectividad y seguridad, sin embargo, también se están haciendo esfuerzos en vías de administración menos invasivas y menos requirentes de servicios de salud (autoadministrables) por lo tanto, es necesario conocer la opinión de los especialistas.  Objetivo:  Determinar las preferencias sobre la vía de administración de medicamentos para el tratamiento de AR por parte de médicos reumatólogos.  Metodología:  se realizó un estudio de corte transversal en reumatólogos del Ecuador en 2017. La información fue recolectada a través de una encuesta diseñada para esta investigación.  Resultados:  el 61,5% de los médicos prefieren la vía subcutánea, principalmente la autoadministrada. El 73% de los médicos cree que el paciente está preparado para la autoadministración sin embargo perciben que el nivel educativo puede ser un factor importante en su contra. La mayoría de profesionales basa su preferencia en el confort y seguridad del paciente.  Conclusiones:  la percepción de los médicos en general se baja en la disminución de la invasividad y el incremento de la seguridad, la percepción de los profesionales sobre las vías autoadministrables se centra en la preparación de los pacientes como una barrera, la vía oral es un objetivo importante y esperable por los profesionales.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Drugs for the management of rheumatoid arthritis (RA), especially the biological and recently approved, are in a process of reducing the invasiveness of its route of administration. Therapeutic research advances every day in the development of new formulas that are based on greater effectiveness and safety, however, efforts are also being made in less invasive administration routes and less demanding of health services (self-administered). Therefore, it is necessary to know the opinion of the specialists.  Objective:  To determine the preferences on the route of administration of medications for the treatment of RA by rheumatologists.  Methodology:  A cross-sectional study was carried out in rheumatologists from Ecuador in 2017. The information was collected through a survey designed for this research.  Results:  The subcutaneous route was preferred by 61.5% of doctors, mainly self-administered. Seventy three percent of doctors believe that the patient is prepared for self-administration, however, they perceive that the educational level can be an important factor against it. Most professionals base their preference on patient comfort and safety.  Conclusions:  The perception of physicians in general is based on the decrease of invasiveness and the increase of safety. The perception of professionals on self-administered routes is focused on the preparation of patients as a barrier while the oral route is a important and expected objective of the professionals.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[vías de administración de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[educación del paciente.]]></kwd>
<kwd lng="en"><![CDATA[rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[drug administration routes]]></kwd>
<kwd lng="en"><![CDATA[patient education.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seemayer]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Distler]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Kuchen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Müller-Ladner]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Michel]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Neidhart]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis]]></article-title>
<source><![CDATA[Z Rheumatol]]></source>
<year>2001</year>
<volume>60</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>309-18</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Picerno]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ferro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Adinolfi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Valentini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tani]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alunno]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[One year in review]]></article-title>
<source><![CDATA[Clin Exp Rheumatol]]></source>
<year>2015</year>
<volume>33</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>551-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McInnes]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Schett]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pathogenesis of rheumatoid arthritis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>365</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2205-19</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Weinblatt]]></surname>
<given-names><![CDATA[ME.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis.]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2001</year>
<volume>358</volume>
<numero>9285</numero>
<issue>9285</issue>
<page-range>903-11</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duró Pujol]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Reumatología clínica]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Amsterdam ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turesson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Fallon]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[Crowson]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Gabriel]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Matteson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2002</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>62-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gabriel]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Crowson]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Kremers]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Doran]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Turesson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Fallon]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[Matteson]]></surname>
<given-names><![CDATA[EL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival in rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2003</year>
<volume>48</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>54-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molenaar]]></surname>
<given-names><![CDATA[ETH]]></given-names>
</name>
<name>
<surname><![CDATA[Voskuyl]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Dinant]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bezemer]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Boers]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dijkmans]]></surname>
<given-names><![CDATA[BAC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2004</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>36-42</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Furst]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Bharat]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Curtis]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Kavanaugh]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Kremer]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.]]></article-title>
<source><![CDATA[Arthritis Care Res]]></source>
<year>2012</year>
<volume>64</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>625-39</page-range><publisher-loc><![CDATA[Hoboken ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Saag]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Bridges]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Akl]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Bannuru]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.]]></article-title>
<source><![CDATA[Arthritis Care Res.]]></source>
<year>2016</year>
<volume>68</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-25</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Landewé]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Breedveld]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Buch]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Burmester]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dougados]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2014</year>
<volume>73</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>492-509</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Landewé]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Breedveld]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Dougados]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Emery]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gaujoux-Viala]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2010</year>
<volume>69</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>964-75</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Aletaha]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bijlsma]]></surname>
<given-names><![CDATA[JWJ]]></given-names>
</name>
<name>
<surname><![CDATA[Breedveld]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Boumpas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Burmester]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treating rheumatoid arthritis to target: recommendations of an international task force.]]></article-title>
<source><![CDATA[Ann Rheum Dis.]]></source>
<year>2010</year>
<volume>69</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>631-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Vollenhoven]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Fleischmann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[García Meijide]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2012</year>
<volume>367</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>508-19</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleischmann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kremer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cush]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schulze-Koops]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Connell]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Bradley]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2012</year>
<volume>367</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>495-507</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lard]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Visser]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Speyer]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[vander Horst-Bruinsma]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Zwinderman]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Breedveld]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Hazes]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early versus delayed treatment in patients with recent-onset rheumatoid arthritis]]></article-title>
<source><![CDATA[Am J Med.]]></source>
<year>2001</year>
<volume>111</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>446-51</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wells]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Verhoeven]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Felson]]></surname>
<given-names><![CDATA[DT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.]]></article-title>
<source><![CDATA[Arthritis Rheum.]]></source>
<year>2000</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Nies]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Tsonaka]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gaujoux-Viala]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fautrel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[van der Helm-van Mil]]></surname>
<given-names><![CDATA[AH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist?]]></article-title>
<source><![CDATA[Ann Rheum Dis.]]></source>
<year>2015</year>
<volume>74</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>806-12</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van der Heide]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Bijlsma]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Heurkens]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[van Booma-Frankfort]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[van der Veen]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effectiveness of early treatment with «second-line» antirheumatic drugs. A randomized, controlled trial.]]></article-title>
<source><![CDATA[Ann Intern Med.]]></source>
<year>1996</year>
<volume>124</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>699-707</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Del Rincon]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Battafarano]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Escalante]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Care Res]]></source>
<year>2015</year>
<volume>67</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>940-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nell]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Machold]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Eberl]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Stamm]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Uffmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2004</year>
<volume>43</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>906-14</page-range><publisher-loc><![CDATA[Oxford ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emery]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kvien]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
<name>
<surname><![CDATA[Combe]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Freundlich]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ferdousi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination etanercept and methotrexate provides better disease control in very early (&lt;=4 months) versus early rheumatoid arthritis (&gt;4 months and &lt;2 years)]]></article-title>
<source><![CDATA[Ann Rheum Dis.]]></source>
<year>2012</year>
<volume>71</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>989-92</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gadallah]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Boulos]]></surname>
<given-names><![CDATA[DNK]]></given-names>
</name>
<name>
<surname><![CDATA[Gebrel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dewedar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Morisky]]></surname>
<given-names><![CDATA[DE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of rheumatoid arthritis patients&#8217; adherence to treatment]]></article-title>
<source><![CDATA[Am J Med Sci]]></source>
<year>2015</year>
<volume>349</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>151-6</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joplin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[van der Zwan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Joshua]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[PKK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication adherence in patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[BioMed Res Int]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salt]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Frazier]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence to disease modifying anti-rheumatic drugs in rheumatoid arthritis patients]]></article-title>
<source><![CDATA[Orthop Nurs Natl Assoc Orthop Nurses.]]></source>
<year>2010</year>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>260-75</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van den Bemt]]></surname>
<given-names><![CDATA[BJF]]></given-names>
</name>
<name>
<surname><![CDATA[Zwikker]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
<name>
<surname><![CDATA[van den Ende]]></surname>
<given-names><![CDATA[CHM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication adherence in patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Expert Rev Clin Immunol.]]></source>
<year>2012</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>337-51</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Sandoval]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Calatrava]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Crespo Palomo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Galván Cervera]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El papel del metotrexato subcutáneo en jeringas precargadas (Metoject®) en el tratamiento de la artritis reumatoide.]]></article-title>
<source><![CDATA[Arch Med]]></source>
<year>2010</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pedroza León]]></surname>
<given-names><![CDATA[MA.]]></given-names>
</name>
</person-group>
<source><![CDATA[Satisfacción de los pacientes con artritis reumatoide en tratamiento con terapia biológica en HGZ N°1 del IMSS delegación Aguascalientes]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Aguascalientes ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Aguascalientes]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaparro del Moral]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rillo]]></surname>
<given-names><![CDATA[OL]]></given-names>
</name>
<name>
<surname><![CDATA[Benegas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Citera]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado Cocco]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherencia al tratamiento de pacientes con artritis reumatoidea que reciben medicamentos biológicos]]></article-title>
<source><![CDATA[Rev Argent Reumatol]]></source>
<year>2013</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>12-26</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ambuludí Armijos]]></surname>
<given-names><![CDATA[VR.]]></given-names>
</name>
</person-group>
<source><![CDATA[Metrotrexate como tratamiento de artritis reumatoide y sus efectos relacionados con vía de administración en hospital IESS-Loja 2014]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Loja, Ecuador ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de Loja, Area de la Salud Humana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scarpato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Antivalle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Favalli]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Nacci]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Frigelli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bartoli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis.]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2010</year>
<volume>49</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>289-94</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marra]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shojania]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bansback]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Societal preferences for rheumatoid arthritis treatments]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2015</year>
<volume>54</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1816-25</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Louder]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saverno]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cappelleri]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Aten]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Koenig]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient Preferences regarding rheumatoid arthritis Tterapies]]></article-title>
<source><![CDATA[Am Health Drug Benefits.]]></source>
<year>2016</year>
<numero>2</numero>
<issue>2</issue>
<page-range>84-93</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alten]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Krüger]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rellecke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schiffner-Rohe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Behmer]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Schiffhorst]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nolting]]></surname>
<given-names><![CDATA[HD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach.]]></article-title>
<source><![CDATA[Patient Prefer Adherence.]]></source>
<year>2016</year>
<volume>10</volume>
<page-range>2217-28</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartzman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[James Morgan]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does route of administration affect the outcome of TNF antagonist therapy?]]></article-title>
<source><![CDATA[Arthritis Res Ther.]]></source>
<year>2004</year>
<volume>6</volume>
<numero>Suppl 2</numero>
<issue>Suppl 2</issue>
<page-range>S19-23</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chilton]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Collett]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment choices, preferences and decision-making by patients with rheumatoid arthritis.]]></article-title>
<source><![CDATA[Musculoskeletal Care]]></source>
<year>2008</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
